Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is 1 of the stocks with explosive maturation potential. On February 19, Madrigal Pharmaceuticals announced the net study for 2025, which was driven by the palmy motorboat of Rezdiffra, the archetypal approved attraction for MASH. Full-year nett income reached $958.4 million, with Q4 gross unsocial hitting $321.1 million, much than tripling the erstwhile year’s quarterly results. By the extremity of 2025, the diligent basal connected Rezdiffra grew to implicit 36,250, up from ~29,500 successful Q3.

The institution importantly evolved from a single-product entity into a diversified biopharmaceutical person with a pipeline of much than 10 programs. Key strategical expansions see licensing an oral GLP-1 receptor agonist, a Phase 2 oral DGAT-2 inhibitor called ervogastat, and six preclinical siRNA programs. These assets are intended to make operation therapies anchored by Rezdiffra to code assorted diligent subtypes and familial drivers of MASH. Additionally, Madrigal secured semipermanent marketplace exclusivity for Rezdiffra done a patent hold lasting until 2045 and initiated its planetary rollout with a motorboat successful Germany.

Looking toward 2026, Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) expects continued double-digit maturation successful the MASH marketplace contempt rising gross-to-net impacts, which are projected to scope the precocious 30% range. While the planetary publication remained negligible successful 2025, the US marketplace remains the superior maturation motor with wide first-line security entree and dependable diligent starts. The institution is besides focused connected objective milestones, peculiarly the MAESTRO-NASH outcomes proceedings successful cirrhosis patients, which is connected way to present information successful 2027.

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is simply a biopharmaceutical institution that delivers caller therapeutics for metabolic dysfunction-associated steatohepatitis/MASH successful the US.

While we admit the imaginable of MDGL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Stocks for Beginners with Little Money successful 2026.

Disclosure: None. Follow Insider Monkey connected Google News.